NPPB and hydrops fetalis: However, analysis in other subgroups with more advanced HF (e.g., more reduced ejection fraction and increased NT-proBNP levels) revealed that patients with LVEF < 30% and NT-proBNP above the median benefited more from therapy with empagliflozin [4].